Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported a small mandatory share sale related to equity compensation. On 01/23/2026, he sold 2,390 shares of common stock at $44.908 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and are described as non-discretionary trades. Following this transaction, he beneficially owned 310,493 shares of Twist Bioscience common stock directly.
An affiliate of TWST has filed a Rule 144 notice to sell 2,390 shares of common stock, with an aggregate market value of 107,329.41, through Fidelity Brokerage Services on NASDAQ around 01/23/2026.
These shares were acquired on 01/22/2026 via restricted stock vesting from the issuer as compensation. The filing also shows that Patrick Finn has sold multiple blocks of common stock over the past three months, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported a planned sale of company stock. On 01/13/2026, he sold 3,000 shares of Twist Bioscience common stock at a price of $40 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he adopted on May 8, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Laponis directly beneficially owned 137,031 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported an option exercise and share sale in the company’s stock. On January 13, 2026, he exercised a stock option for 3,279 shares of common stock at an exercise price of $8.82 per share and acquired those shares directly.
On the same date, he sold 23,279 shares of Twist Bioscience common stock at a price of $40 per share in an open-market transaction. After these transactions, Finn directly owned 312,883 shares of common stock. The filing notes that these transactions were carried out under a previously adopted Rule 10b5-1 trading plan put in place on May 13, 2025.
Twist Bioscience Corp's Chief Financial Officer, Adam Laponis, reported an automatic sale of common stock to cover taxes related to equity compensation. On January 9, 2026, he sold 2,738 shares of common stock at a price of $35.261 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and were executed as mandatory "sell to cover" transactions rather than discretionary trades. After this sale, Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.
An affiliate of TWST has filed a Form 144 notice for a proposed sale of 23,279 shares of common stock through Fidelity Brokerage Services LLC, to be sold on NASDAQ around 01/13/2026. The filing lists an aggregate market value of $931,160.00 and notes that 61,148,026 shares of this class were outstanding.
The shares to be sold were acquired mainly through restricted stock vesting, an employee stock purchase plan, and an option granted on 09/29/2017, with acquisition and payment dates between 02/18/2022 and 02/20/2025. The notice also reports that Patrick Finn sold additional common shares over the prior three months on dates including 10/23/2025 and 10/30/2025, with individual transactions such as 2,240 shares for $69,159.78 and 17,606 shares for $553,608.35.
Adam Laponis filed a Form 144 notice to sell 3,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 120000.00. The securities to be sold were acquired via restricted stock vesting from the issuer on three dates: 267 shares on 10/29/2025, 784 shares on 11/20/2025, and 1,949 shares on 01/08/2026, all as compensation. The filing notes that 61,148,026 shares of this class were outstanding.
Over the prior three months, Adam Laponis sold additional common shares: 5,517 shares on 10/30/2025 for gross proceeds of 173,478.20, 887 shares on 11/21/2025 for 23,508.60, and 2,738 shares on 01/09/2026 for 96,544.34. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025. The company announced these early revenue figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. Twist notes that these revenue expectations are preliminary and may change after it completes its internal control, review, and audit procedures, so the final numbers in its quarterly financial statements could differ materially. The company also states that this information is being furnished, not filed, which limits how it is treated under securities law.
Adam Laponis has filed a notice of proposed sale of common stock under Rule 144. The filing covers a planned sale of 2,738 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $96,544.34, when approximately 61,148,026 shares were outstanding and the shares are expected to be sold around 01/09/2026 on NASDAQ.
The 2,738 shares were acquired on 01/08/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller reported additional sales of common stock, including 2,517 shares for gross proceeds of $82,864.17, 5,517 shares for $173,478.20, and 887 shares for $23,508.60.